Global Single-use Upstream Bioprocessing Market | Key Players are Danaher Corporation (Cytiva), Sartorius AG, Thermo Fisher Scientific, Inc., Merck KGaA, Corning Incorporated, Pall Corporation, General Electric Company (GE Healthcare), Eppendorf AG

The market size of the Global Single-use Upstream Bioprocessing Market in the year 2021 is valued at 9.03 billion and is predicted to reach 34.54 billion by the year 2030 at an 16.6% CAGR during the projected period.

Request for Sample Pages:

Upstream bioprocessing, which creates cell lines and cultivates them so that the cells can be grown by harvesting, is the initial bioprocessing step. Today’s cell growth techniques result in bioreactors with considerably larger titers, more accuracy, and lower time limitations. The disposal of disposables in the bioprocessing sector has increased due to the benefits provided by single-use technology (SUT), such as the significant decrease in capital cost and facility building time. The industry for single-use bioprocessing has increased by double digits as a result. Rising manufacturing techniques’ productive capacities, the removal of duplicate processes, direct cost savings from cheap labour and material costs, and reduced energy consumption and water use are all contributing reasons to the market’s expansion. One of the key trends influencing the market for single-use bioprocessing is the increase in suppliers offering durable disposables for the industrial production of biopharmaceuticals. Additionally, the development of automation in the bioprocessing sector has drastically increased the efficiency of biomanufacturing. The need to reduce upfront costs, shorten production changeover times between batches, significantly speed up production, reduce the risk of cross-contamination between samples, require no clean-in-place and steam-in-place (CIP/SIP) operations, and simplify piping and instrumentation procedures are all contributing significantly to the market’s growth.

There are still significant difficulties regarding the disposal of solid waste products from this alternative technology. Such products can’t be recycled because separating the components into homogeneous parts takes a lot of work. The majority of single-use systems and their features are therefore unsuitable for recycling. Currently, the contamination of single-use bioprocessing systems by extractables and leachables is not governed by any specific laws or regulations. Since they are made of processed plastic materials, single-use bioprocessing products commonly face contamination from the container due to leachables. Due to their potential implications on product quality and patient health, significant worries about extractables and leachables coming from the components of single-use bioprocessing systems may limit market growth.

Market Segmentation:

The Single-use Upstream Bioprocessing Market is segmented on the basis of Product, Scale, and End-Use. Based on Product, the market is segmented as Single-use Bioreactors, Single-use Mixers, Single-use Media Bags, Single-use Filters, Single-use Sampling Systems, Single-use Connectors, and Others. Based on Scale, the market is segmented as Preclinical / Clinical and Commercial. Based on End-Use, the market is segmented as Biopharmaceutical Manufacturers and CMOs & CROs.

Based on Product, the Single-use Bioreactors segment is accounted as a major contributor in the Single-use Upstream Bioprocessing Market

The Single-use Bioreactors segment currently dominates the global single-use bioprocessing market, and this trend is anticipated to persist over the course of the projected period. The segment is primarily being driven by small businesses and start-ups adopting single-use bioreactors more frequently, technological developments in these goods, and the benefits these products provide. Numerous biopharmaceutical firms have fought the race to create an effective vaccine against the SARS-CoV-2 virus. As a result, the need for single-use bioreactors has skyrocketed. With their flexibility, Single-use Bioreactors have effectively met the rising demand for biopharmaceuticals while overcoming issues with standard bioreactors. One of the main business drivers of investing in single-use bioreactor technology is acknowledged to be flexibility. In the upcoming years, it is projected that the use of disposable bioreactors will increase due to the rising demand for highly effective medicines that do not necessitate a huge number of bioreactors.

Based on End Use, the Single-use Bioreactors segment is accounted as a major contributor in the Single-use Upstream Bioprocessing Market.

In the forecast period, the category of biopharmaceutical manufacturers will account for the biggest revenue and dominate the market for single-use bioprocessing. The growing acceptance of disposables by contract manufacturers has been extremely beneficial to the biopharmaceutical manufacturing industry. Numerous bio manufacturers have started investing in extending their manufacturing capacity through the installation of new disposable equipment in order to keep up with the shifting client demands for vaccine manufacturing and related bioprocessing services. The COVID-19 pandemic has increased investment in the bioprocessing sector, which has, in turn, fuelled the demand for single-use bioprocessing. To meet the current market’s expectations, market players are investing a significant amount in developing innovative single-use goods, such as smart single-use linked temperature sensors.

In the region, the North America Single-use Upstream Bioprocessing Market holds a significant revenue share.

North America will lead the single-use bioprocessing market with a large revenue share throughout the projected period.

The region’s supremacy has been supported tremendously by the expansion of biopharmaceutical R&D as well as the existence of large-scale biopharmaceutical manufacturing facilities in the United States. Furthermore, North America has many contracts manufacturing companies that rely on disposables in their everyday operations. The United States is expected to lead North America’s single-use upstream bioprocessing industry.

The ageing population, the development of ground-breaking single-use bioprocessing technologies in industrialised nations such as the United States and Canada, and the growing desire for bioactive compounds are all significant market growth factors in this area.

Competitive Landscape

The key players in the Single-use Upstream Bioprocessing Market have shifted their focus toward bio-based components for product manufacturing and are initiating significant strategies such as mergers, acquisitions, and through partnerships with regional and international companies to expand their product offerings and expand their global market presence. Some of the major key players in the Single-use Upstream Bioprocessing Market are  Danaher Corporation (Cytiva), Sartorius AG, Thermo Fisher Scientific, Inc., Merck KGaA, Corning Incorporated, Pall Corporation, General Electric Company (GE Healthcare), Eppendorf AG, Rentschler Biopharma SE, Lonza, Meissner Filtration Products, Inc., JM BioConnect, Boehringer Ingelheim GmbH, and Infors AG.

Curious about this latest version of the report?  Obtain Report Details @

Segmentation of Single-use Upstream Bioprocessing Market-

By Product

  • Single-use Bioreactors
  • Single-use Mixers
  • Single-use Media Bags
  • Single-use Filters
  • Single-use Sampling Systems
  • Single-use Connectors
  • Others

By Scale

  • Preclinical / Clinical
  • Commercial

By End-Use

  • Biopharmaceutical Manufacturer
  • CMOs & CROs

By Region-

North America-

  • The US
  • Canada
  • Mexico


  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe


  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

For More Information @

Contact Information:

+1 551 226 6109 Email:

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.